168 related articles for article (PubMed ID: 35647972)
1. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy.
Jethva J; Bhagat P; Prajapati K; Tank G
Indian J Ophthalmol; 2022 Jun; 70(6):2020-2023. PubMed ID: 35647972
[TBL] [Abstract][Full Text] [Related]
2. Role of ripasudil as an adjunct treatment in the management of pseudoexfoliative glaucoma.
Mohapatra S; Thakur S; Panda BB; Das P
Indian J Ophthalmol; 2023 Jul; 71(7):2756-2759. PubMed ID: 37417116
[TBL] [Abstract][Full Text] [Related]
3. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
Inoue T; Tanihara H
Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
[TBL] [Abstract][Full Text] [Related]
7. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
Komizo T; Ono T; Yagi A; Miyata K; Aihara M
Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
[TBL] [Abstract][Full Text] [Related]
9. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
Honjo M; Tanihara H
Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.
Tanihara H; Kakuda T; Sano T; Kanno T; Gunji R
BMC Ophthalmol; 2020 Jul; 20(1):275. PubMed ID: 32646383
[TBL] [Abstract][Full Text] [Related]
11. Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection.
Kusuhara S; Nakamura M
Clin Ophthalmol; 2020; 14():1229-1236. PubMed ID: 32440089
[TBL] [Abstract][Full Text] [Related]
12. Ripasudil: first global approval.
Garnock-Jones KP
Drugs; 2014 Dec; 74(18):2211-5. PubMed ID: 25414122
[TBL] [Abstract][Full Text] [Related]
13. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study.
Futakuchi A; Morimoto T; Ikeda Y; Tanihara H; Inoue T;
Sci Rep; 2020 Jun; 10(1):10308. PubMed ID: 32587304
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
Inoue K; Okayama R; Shiokawa M; Ishida K; Tomita G
Int Ophthalmol; 2018 Feb; 38(1):93-98. PubMed ID: 28063100
[TBL] [Abstract][Full Text] [Related]
15. Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.
Terao E; Nakakura S; Fujisawa Y; Fujio Y; Matsuya K; Kobayashi Y; Tabuchi H; Yoneda T; Fukushima A; Kiuchi Y
Curr Eye Res; 2017 May; 42(5):738-742. PubMed ID: 27911106
[TBL] [Abstract][Full Text] [Related]
16. The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15.
Sakata R; Fujishiro T; Saito H; Honjo M; Shirato S; Aihara M
Adv Ther; 2021 Jul; 38(7):3760-3770. PubMed ID: 34028695
[TBL] [Abstract][Full Text] [Related]
17. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
[TBL] [Abstract][Full Text] [Related]
18. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
[TBL] [Abstract][Full Text] [Related]
19. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
[TBL] [Abstract][Full Text] [Related]
20. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
